191 related articles for article (PubMed ID: 30668625)
1. Chronic intermittent hypoxia accelerates liver fibrosis in rats with combined hypoxia and nonalcoholic steatohepatitis via angiogenesis rather than endoplasmic reticulum stress.
Wu W; Li W; Wei J; Wang C; Yao Y; Zhu W; He W; Zhou W; Liu J
Acta Biochim Biophys Sin (Shanghai); 2019 Feb; 51(2):159-167. PubMed ID: 30668625
[TBL] [Abstract][Full Text] [Related]
2. [Neovascularization aggravated hepatic fibrosis in combined hypoxia NASH rat model].
Liu J; Wu W; Gu DH; Liu CY; Dong Q; Yao YL; Wang CS; Chen XP; Yang HX
Zhonghua Gan Zang Bing Za Zhi; 2017 Jul; 25(7):517-522. PubMed ID: 29055990
[No Abstract] [Full Text] [Related]
3. Chronic intermittent hypoxia promotes the development of experimental non-alcoholic steatohepatitis by modulating Treg/Th17 differentiation.
Liu J; Li W; Zhu W; He W; Zhao H; Xiang Y; Liu C; Wu W
Acta Biochim Biophys Sin (Shanghai); 2018 Dec; 50(12):1200-1210. PubMed ID: 30379980
[TBL] [Abstract][Full Text] [Related]
4. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS
Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162
[TBL] [Abstract][Full Text] [Related]
5. Glucose regulated protein 78 is potentially an important player in the development of nonalcoholic steatohepatitis.
Zhou X; Han D; Yang X; Wang X; Qiao A
Gene; 2017 Dec; 637():138-144. PubMed ID: 28951310
[TBL] [Abstract][Full Text] [Related]
6. Rnd3/RhoE Modulates Hypoxia-Inducible Factor 1α/Vascular Endothelial Growth Factor Signaling by Stabilizing Hypoxia-Inducible Factor 1α and Regulates Responsive Cardiac Angiogenesis.
Yue X; Lin X; Yang T; Yang X; Yi X; Jiang X; Li X; Li T; Guo J; Dai Y; Shi J; Wei L; Youker KA; Torre-Amione G; Yu Y; Andrade KC; Chang J
Hypertension; 2016 Mar; 67(3):597-605. PubMed ID: 26781283
[TBL] [Abstract][Full Text] [Related]
7. Liver-specific loss of Perilipin 2 alleviates diet-induced hepatic steatosis, inflammation, and fibrosis.
Najt CP; Senthivinayagam S; Aljazi MB; Fader KA; Olenic SD; Brock JR; Lydic TA; Jones AD; Atshaves BP
Am J Physiol Gastrointest Liver Physiol; 2016 May; 310(9):G726-38. PubMed ID: 26968211
[TBL] [Abstract][Full Text] [Related]
8. Molecular drivers of non-alcoholic steatohepatitis are sustained in mild-to-late fibrosis progression in a guinea pig model.
Ipsen DH; Skat-Rørdam J; Tsamouri MM; Latta M; Lykkesfeldt J; Tveden-Nyborg P
Mol Genet Genomics; 2019 Jun; 294(3):649-661. PubMed ID: 30759275
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Study of Multiple Stages Progressing to Nonalcoholic Steatohepatitis with Subsequent Fibrosis in SD Rats.
Wang L; Wu S; Cai M; Ma J; Li S; Li M; Xu Y; Wei L; Shang J
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28820447
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis.
Tamaki Y; Nakade Y; Yamauchi T; Makino Y; Yokohama S; Okada M; Aso K; Kanamori H; Ohashi T; Sato K; Nakao H; Haneda M; Yoneda M
J Gastroenterol; 2013 Apr; 48(4):491-503. PubMed ID: 22886508
[TBL] [Abstract][Full Text] [Related]
11. Placental growth factor silencing ameliorates liver fibrosis and angiogenesis and inhibits activation of hepatic stellate cells in a murine model of chronic liver disease.
Li X; Yao QY; Liu HC; Jin QW; Xu BL; Zhang SC; Tu CT
J Cell Mol Med; 2017 Oct; 21(10):2370-2385. PubMed ID: 28378526
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia inducible factor-1 promotes liver fibrosis in nonalcoholic fatty liver disease by activating PTEN/p65 signaling pathway.
Han J; He Y; Zhao H; Xu X
J Cell Biochem; 2019 Sep; 120(9):14735-14744. PubMed ID: 31009107
[TBL] [Abstract][Full Text] [Related]
13. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of isochlorogenic acid B on liver fibrosis in non-alcoholic steatohepatitis of mice.
Liu X; Huang K; Niu Z; Mei D; Zhang B
Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):144-153. PubMed ID: 30180301
[TBL] [Abstract][Full Text] [Related]
16. Elevation of liver endoplasmic reticulum stress in a modified choline-deficient l-amino acid-defined diet-fed non-alcoholic steatohepatitis mouse model.
Muraki Y; Makita Y; Yamasaki M; Amano Y; Matsuo T
Biochem Biophys Res Commun; 2017 May; 486(3):632-638. PubMed ID: 28322783
[TBL] [Abstract][Full Text] [Related]
17. Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis.
Cai CX; Buddha H; Castelino-Prabhu S; Zhang Z; Britton RS; Bacon BR; Neuschwander-Tetri BA
Dig Dis Sci; 2017 Apr; 62(4):968-978. PubMed ID: 28194671
[TBL] [Abstract][Full Text] [Related]
18. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory stress and altered angiogenesis evoked by very high-fat diets in mouse liver.
Plaza A; Naranjo V; Blonda AM; Cano V; González-Martín C; Gil-Ortega M; Ruiz-Gayo M; Merino B
Endocrinol Diabetes Nutr (Engl Ed); 2019; 66(7):434-442. PubMed ID: 30833154
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease.
Coulon S; Francque S; Colle I; Verrijken A; Blomme B; Heindryckx F; De Munter S; Prawitt J; Caron S; Staels B; Van Vlierberghe H; Van Gaal L; Geerts A
Cytokine; 2012 Aug; 59(2):442-9. PubMed ID: 22658783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
